Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928356 | 1.00 | NFE2L2 (0.49) | NFE2L2KMT2ARAB9ATDP1EGFR | |
| SCHEMBL3720477 | 0.79 | MAPT (0.51) | KMT2ARAB9ANPC1MAPTGAA | |
| SCHEMBL9364332 | 0.79 | MAPT (0.51) | KMT2ARAB9ANPC1MAPTGAA | |
| SCHEMBL3720479 | 0.79 | MAPT (0.51) | KMT2ARAB9ANPC1MAPTGAA | |
| SCHEMBL4365621 | 0.79 | NFE2L2 (0.48) | NFE2L2KMT2ARAB9ATDP1EGFR | |
| SCHEMBL9507418 | 0.79 | KMT2A (0.49) | KMT2ARAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL9507425 | 0.79 | KMT2A (0.49) | KMT2ARAB9ANPC1MAPTL3MBTL1 | |
| SCHEMBL4364965 | 0.77 | NFE2L2 (0.46) | NFE2L2KMT2ARAB9ATDP1EGFR | |
| SCHEMBL4506296 | 0.77 | NFE2L2 (0.46) | NFE2L2KMT2ARAB9ATDP1EGFR | |
| SCHEMBL9509534 | 0.75 | TDP1 (0.47) | NFE2L2KMT2ARAB9ATDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203700-A1 | Azolylmethyloxiranes, Their Use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them | BASF SE (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203700-A1 | Azolylmethyloxiranes, Their Use for Controlling Phytopathogenic Fungi, and Compositions Comprising Them | CBR3, NAT1, C5 | NFE2L2 1164/4885KMT2A 1226/4885RAB9A 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.